Article

Sugar Metabolism in Liver Implicated in Liver Cancer Diagnosis

Liver tumors found to stop using fructose.

Monitoring sugar metabolism in the liver could be a new and significant diagnostic marker for liver cancer, a recent study found.

The study, published in Nature Cell Biology, indicates that the gene ketohexokinase or fructokinase (KHK) expresses differently in normal liver tissues compared with liver tumors.

Liver cancer cells were found to have a significantly reduced level of fructose metabolism compared with healthy cells.

“Normal liver cells catalyze both glucose and fructose for energy, amino acid and lipid production,” said researcher Zhimin Lu, MD, PhD. “However, we found that liver tumors stopped using fructose. Thus, monitoring fructose metabolism could potentially be used for liver cancer diagnosis.”

This reduction of fructose metabolism in liver tumors cells is caused by aberrant alternative splicing of the KHK gene. This process results in the expression in a variety of the gene product KHK-A, which lost the ability to process fructose.

“KHK-A has 2 enzymatic activities, sugar kinase and protein kinase,” Lu said. “We discovered that KHK-A was not only a sugar kinase but also a protein kinase.”

The study was able to show that KHK-A’s protein kinase activity enhances tumor cell DNA and RNA synthesis.

“It is this protein kinase activity that we believe can be targeted to treat the liver tumor,” Lu said. “Our study revealed a pivotal mechanism underlying how liver and liver tumor cells use fructose and highlight the instrumental role of the KHK-A protein in promoting tumor development.”

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards